Nucleobindin-2 mRNA level is down regulated in KRAS-mutation lung cancer cell lines compared with EGFR/BRAF/KRAS wild-type lung cancer cell lines

Abstract

Ten of lung cancer cell lines with EGFR/BRAF/KRAS wildtype (H1299, H1819, HCC95, H838, H1437, H661, HCC15, HCC78, H1648, HCC193) and eleven of lung cancer cell lines with KRAS-mutation [KRAS-G12C (H2122, HCC44, H1792, HCC4017, H358), KRAS-G12V (H441), KRAS-G12D (HCC515), KRAS-G12R (H1264, H157), KRAS-G12A (H2009), KRAS-Q61H (H460)] were used [3]. Nucleobindin-2 mRNA level was analyzed by RT-qPCR as previously rescribed [3]. Primers and probes for Nucleobindin-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were obtained from Ori Gene Technologies (MK203097; Rockville, MD, USA;) and Applied Biosystems (Assay ID: Hs99999905_m1; Tokyo, Japan;), respectively. To normalize the amount of input cDNA, quantitative analysis was performed using the GAPDH as an internal reference. Relative expression values were computed using the comparative cycle threshold (Ct) method. All data in the figure are presented as mean ± standard deviation and were analyzed using one-way ANOVA to compare the means of all the groups. Turkey-Kramer multiple comparisons method was used to determine statistical differences between the means, with p < 0.05 deemed statistically significant using the InStat 2.00 program.